{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:18:46Z","timestamp":1792703926494,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.eururo.2021.12.005","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T17:48:02Z","timestamp":1640281682000},"page":"34-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu\u00e9rin\u2013exposed High-risk Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"82","author":[{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"B\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Brausi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Persad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Palou-Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Soloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Brothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Alfred Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.12.005_b0005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0010","series-title":"EAU guidelines: non-muscle-invasive bladder cancer","author":"Babjuk","year":"2021"},{"key":"10.1016\/j.eururo.2021.12.005_b0015","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2021.12.005_b0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0025","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0030","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0035","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0040","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2021.12.005_b0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/BLC-201510","article-title":"A systematic review of outcome reporting, definition and measurement heterogeneity in non-muscle invasive bladder cancer effectiveness trials of adjuvant, prophylactic treatment after transurethral resection","volume":"7","author":"Veskimae","year":"2021","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2021.12.005_b0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2021.12.005_b0060","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.12.005_b0065","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.12.005_b0070","series-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry","author":"US Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.eururo.2021.12.005_b0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.12.005_b0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2021.12.005_b0085","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.2021.39.6_suppl.510","article-title":"Phase II\/III clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients","volume":"39","author":"Chamie","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.12.005_b0090","first-page":"e72","article-title":"Phase 3 results of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2021.12.005_b0095","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2021.39.15_suppl.4541","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"39","author":"Black","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.12.005_b0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.12.005_b0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.12.005_b0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0115","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0120","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.euo.2018.08.013","article-title":"Using grade of recurrent tumor to guide further therapy while on bacillus Calmette-Guerin: low-grade recurrences are not benign","volume":"2","author":"Li","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2021.12.005_b0125","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1111\/j.1464-410X.2011.10894.x","article-title":"Prognostic significance of bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer","volume":"110","author":"Shirakawa","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.12.005_b0130","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2016.02.031","article-title":"Papillary recurrence of bladder cancer at first evaluation after induction bacillus Calmette-Guerin therapy: implication for clinical trial design","volume":"70","author":"Mmeje","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2018.09.028","article-title":"Prognostic implication of the United States Food and Drug Administration-defined BCG-unresponsive disease","volume":"75","author":"Li","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0140","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0022-5347(17)40067-X","article-title":"The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin","volume":"143","author":"Bretton","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0145","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","article-title":"Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy","volume":"152","author":"Nadler","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0150","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","article-title":"Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer","volume":"55","author":"Brake","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.12.005_b0155","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0022-5347(17)39546-0","article-title":"Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor","volume":"144","author":"Coplen","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0160","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-5347(17)42722-4","article-title":"Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors","volume":"139","author":"Kavoussi","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/BLC-150039","article-title":"Bacillus Calmette-Guerin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease","volume":"2","author":"Steinberg","year":"2016","journal-title":"Bladder Cancer"},{"issue":"306","key":"10.1016\/j.eururo.2021.12.005_b0170","first-page":"e1","article-title":"Does switching the bacillus Calmette-Guerin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guerin therapy?","volume":"36","author":"Niwa","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.12.005_b0175","series-title":"Presented at the Johns Hopkins Greenberg Bladder Cancer Institute and American Urological Association Translational Research Collaboration meeting on Drug Development in NMIBC from Scientific, Regulatory, Clinician, and Patient Perspectives","article-title":"Regulatory considerations in the BCG-na\u00efve NMIBC setting","author":"Weinstock","year":"2021"},{"key":"10.1016\/j.eururo.2021.12.005_b0180","series-title":"Presented at the Genitourinary Cancers Symposium","article-title":"Meet the regulators: history of FDA perspective and drug development in non-muscle invasive bladder cancer","author":"Lerner","year":"2021"},{"key":"10.1016\/j.eururo.2021.12.005_b0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer\u2013Genito-Urinary Group phase III trial (30906)","volume":"173","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0190","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0195","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials","volume":"164","author":"Van Der Meijden","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.005_b0200","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.12.005_b0205","series-title":"Clinical trials design, conduct, and analysis","author":"Meinert","year":"1986"},{"key":"10.1016\/j.eururo.2021.12.005_b0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/01.wnl.0000438226.10353.1c","article-title":"The questionable use of unequal allocation in confirmatory trials","volume":"82","author":"Hey","year":"2014","journal-title":"Neurology"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821022132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821022132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:11:44Z","timestamp":1759583504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283821022132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0302283821022132"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.12.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu\u00e9rin\u2013exposed High-risk Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}